Open AccessMortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19
Author(s) -
Jonathan Christianto Sutadji,
Agung Dwi Wahyu Widodo,
Danti Nur Indiastuti
Publication year - 2021
Publication title -
folia medica indonesiana
Language(s) - English
Resource type - Journals
eISSN - 2599-056X
pISSN - 2355-8393
DOI - 10.20473/fmi.v57i2.21929
Subject(s) - medicine , cytokine storm , proinflammatory cytokine , mortality rate , covid-19 , randomized controlled trial , disease , immunology , inflammation , infectious disease (medical specialty)
Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.